"Safety and efficacy of pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC)." by David B. Page

Selected Works of Walter J. Urba, MD, PhD

Article

Safety and efficacy of pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC).

Journal of Clinical Oncology (2018)

David B. Page, Providence Portland Medical Center
Isaac K Kim
Katherine Sanchez
Nicole Moxon
Staci L. Mellinger
Alison Katherine Conlin, Memorial Sloan Kettering Cancer Center
Anupama Kurup Acheson, Providence Portland Medical Center
Kelly Shea Perlewitz, Cancer Institute
Stacy K. Lewis, Young Survival Coalition
Kathleen A. Kemmer
Zahi Ibrahim Mitri, University of Texas MD Anderson Cancer Center
Reva K Basho, University of Texas MD Anderson Cancer Center
Emily Riffle
Jenny Ahn
Joanna Pucilowska
Maritza Martel, Yale University
Walter John Urba
Heather L. McArthur, Cedars-Sinai Medical Center

Link

Disciplines

Publication Date

June 1, 2018

Citation Information

David B. Page, Isaac K Kim, Katherine Sanchez, Nicole Moxon, et al.. "Safety and efficacy of pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC)." Journal of Clinical Oncology (2018)
Available at: http://works.bepress.com/walter-urba/18/